Urinary estrogen metabolites and breast cancer: A combined analysis of individual level data

International Journal of Biological Markers

Volumn 28, Issue 1, 2013, Pages 3-16

  Dallal, Cher M ^a   Stone, Roslyn A ^a   Cauley, Jane A ^a   Ness, Roberta B ^b   Vogel, Victor G ^c   Fentiman, Ian S ^d   Fowke, Jay H ^e   Krogh, Vittorio ^f   Loft, Steffen ^g   Meilahn, Elaine N ^h   Muti, Paola ⁱ   Olsen, Anja ^j   Overvad, Kim ^k   Sieri, Sabina ^f   Tjønneland, Anne ^j   Ursin, Giske ^l   Wellejus, Anja ^g   Taioli, Emanuela ^m  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d GUY S HOSPITAL   (United Kingdom)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h MARION DUPONT SCOTT EQUINE MEDICAL CENTER   (United States)

ⁱ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^j DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^k AARHUS UNIVERSITY   (Denmark)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

more..

Author keywords

Epidemiology; Estrogen metabolite ratio; Menopause

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; ESTRIOL; ESTROGENS; FEMALE; HUMANS; ODDS RATIO; POSTMENOPAUSE; PREMENOPAUSE; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84876710718     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/JBM.2012.9353     Document Type: Article

References (53)

1. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-33.
2. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002; 7: 3-15.
3. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-16.
4. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008; 630: 148-65.
5. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006; 98: 1406-15.
6. Sturgeon SR, Potischman N, Malone KE, et al. Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes Control 2004; 15: 45-53.
7. Lippert TH, Seeger H, Mueck AO. The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 2000; 65: 357-69.
8. Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and malignant disease. Maturitas 2002; 43: 1-10.
9. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-82.
10. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A 1988; 85: 7831-5.
11. Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003; 72: 877-83.
12. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006; 54: 72-7.
13. Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984; 259: 4840-5.
14. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998; 19: 1-27.
15. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78: 1250-5.
16. Fowke JH, Qi D, Bradlow HL, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 2003; 68: 65-72.
17. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6: 505-9.
18. Kabat GC, O'Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology 2006; 17: 80-8.
19. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16 alphahydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998; 27: 294-9.
20. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11: 635-40.
21. Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91: 1067-72.
22. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005; 14: 2137-42.
23. Westerlind KC, Gibson KJ, Wolfe P. The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease-risk assessment. Steroids 1999; 64: 233-43.
24. Bradlow HL, Sepkovic DW, Klug T, Osborne MP. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998; 63: 406-13.
25. Klug TL, Bradlow HL, Sepkovic DW. Monoclonal antibodybased enzyme immunoassay for simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in urine. Steroids 1994; 59: 648-55.
26. Falk RT, Rossi SC, Fears TR, et al. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid. Cancer Epidemiol Biomarkers Prev 2000; 9: 81-7.
27. Veglia F, Loft S, Matullo G, et al. DNA adducts and cancer risk in prospective studies: a pooled analysis and a metaanalysis. Carcinogenesis 2008; 29: 932-6.
28. Breslow NE, Day NE. Statistical methods in cancer research. Volume I, The analysis of case-control studies. IARC Sci Publ 1980; 32: 5-338.
29. Eliassen AH, Spiegelman D, Xu X, et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res 2012; 72: 696-706.
30. Xu X, Keefer LK, Ziegler RG, Veenstra TD. A liquid chromatography-mass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. Nat Protoc 2007; 2: 1350-5.
31. Arslan AA, Shore RE, Afanasyeva Y, Koenig KL, Toniolo P, Zeleniuch-Jacquotte A. Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2009; 18: 2273-9.
32. Modugno F, Kip KE, Cochrane B, et al. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer 2006; 118: 1292-301.
33. Cauley JA, Zmuda JM, Danielson ME, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003; 14: 740-4.
34. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008; 17: 2029-35.
35. Fuhrman BJ, Schairer C, Gail MH, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012; 104: 326-39.
36. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 2007; 79: 7813-21.
37. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000; 151: 703-14.
38. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 2003; 12: 1053-60.
39. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res 2006; 8: R39.
40. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004; 96: 1856-65.
41. Bernstein L, Pike MC, Ross RK, Henderson BE. Age at menarche and estrogen concentrations of adult women. Cancer Causes Control 1991; 2: 221-5.
42. Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph JF, Jr. Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am J Med 2006; 119: S16-22.
43. Key TJ, Chen J, Wang DY, Pike MC, Boreham J. Sex hormones in women in rural China and in Britain. Br J Cancer 1990; 62: 631-6.
44. Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res 2001; 61: 3326-9.
45. Jernstrom H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA. Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. Carcinogenesis 2003; 24: 991-1005.
46. Sowers MR, Crawford S, McConnell DS, et al. Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial/ethnic population of women. J Nutr 2006; 136: 1588-95.
47. Xu X, Duncan AM, Merz-Demlow BE, Phipps WR, Kurzer MS. Menstrual cycle effects on urinary estrogen metabolites. J Clin Endocrinol Metab 1999; 84: 3914-8.
48. Friedenreich CM. Commentary: improving pooled analyses in epidemiology. Int J Epidemiol 2002; 31: 86-7.
49. Taioli E, Bradlow HL, Garbers SV, et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 1999; 23: 232-7.
50. Lord RS, Bongiovanni B, Bralley JA. Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev 2002; 7: 112-29.
51. Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006; 1766: 63-78.
52. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000; 27: 67-73.
53. Eliassen AH, Ziegler RG, Rosner B, et al. Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 2009; 18: 2860-8.